Immunic Inc's Vidofludimus Calcium Holds Promise for Treating Multiple Sclerosis

Immunic Inc's chief scientific officer, Dr. Hella Kohlhof, highlights the importance of treating multiple sclerosis (MS) with vidofludimus calcium, the company's lead compound. The therapy has shown promising clinical readouts, including slowing or halting disease progression and even improving patient function. Kohlhof expresses optimism about the future of MS treatment, stating that progress in understanding the disease is bringing the field closer to better long-term outcomes.